Literature DB >> 9990007

Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40.

N Tsukamoto1, N Kobayashi, S Azuma, T Yamamoto, J Inoue.   

Abstract

CD40 signaling modulates the immune response at least in part by activation of nuclear factor kappaB (NFkappaB). It has been shown that two distinct domains in the CD40 cytoplasmic tail (cyt), namely cyt-N and cyt-C, independently activate NFkappaB. Although four members of the tumor necrosis factor receptor-associated factor (TRAF) family, including TRAF2, TRAF3, TRAF5, and TRAF6, bind to the CD40 cyt, how each TRAF protein contributes to the NFkappaB activation by CD40 is not clear. Here we report that TRAF2, TRAF3, and TRAF5 bind cyt-C, whereas TRAF6 binds cyt-N. cyt-N is conserved poorly between human and mouse CD40, while cyt-C is highly conserved. However, single aa substitution of Glu-235 in cyt-N of human CD40 with Ala abolishes the binding of TRAF6 to cyt-N and NFkappaB activation by cyt-N. Conservation of this Glu between mouse and human CD40 strongly suggests that TRAF6 could link cyt-N to signals essential for CD40-mediated immune response. Furthermore, NFkappaB activation by cyt-C is inhibited by a kinase-negative form of NFkappaB-inducing kinase more efficiently than that by cyt-N, consistent with the result that NFkappaB activation by TRAF2 and TRAF5 is inhibited by a kinase-negative form of NFkappaB-inducing kinase more efficiently than that by TRAF6. These results indicate that NFkappaB activating signals emanating from cyt-N and cyt-C are mediated by the different members of the TRAF family and could be regulated in a distinct manner.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990007      PMCID: PMC15446          DOI: 10.1073/pnas.96.4.1234

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation.

Authors:  R M Torres; E A Clark
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

2.  Negative regulation of Rb expression by the p53 gene product.

Authors:  Y Shiio; T Yamamoto; N Yamaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40.

Authors:  S Inui; T Kaisho; H Kikutani; I Stamenkovic; B Seed; E A Clark; T Kishimoto
Journal:  Eur J Immunol       Date:  1990-08       Impact factor: 5.532

4.  Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny.

Authors:  F M Uckun; G L Schieven; I Dibirdik; M Chandan-Langlie; L Tuel-Ahlgren; J A Ledbetter
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

5.  CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells.

Authors:  T B Barrett; G Shu; E A Clark
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

6.  Proliferation and differentiation of human CD5+ and CD5- B cell subsets activated through their antigen receptors or CD40 antigens.

Authors:  T Defrance; B Vanbervliet; I Durand; J Briolay; J Banchereau
Journal:  Eur J Immunol       Date:  1992-11       Impact factor: 5.532

7.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

8.  A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.

Authors:  I Stamenkovic; E A Clark; B Seed
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

9.  Isolated human follicular dendritic cells display a unique antigenic phenotype.

Authors:  F Schriever; A S Freedman; G Freeman; E Messner; G Lee; J Daley; L M Nadler
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

10.  CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells.

Authors:  H H Jabara; S M Fu; R S Geha; D Vercelli
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  35 in total

1.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Authors:  Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

2.  TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.

Authors:  Aristides G Eliopoulos; Elyse R Waites; Sarah M S Blake; Clare Davies; Paul Murray; Lawrence S Young
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.

Authors:  Jin Gohda; Toru Akiyama; Takako Koga; Hiroshi Takayanagi; Sakae Tanaka; Jun-ichiro Inoue
Journal:  EMBO J       Date:  2005-01-27       Impact factor: 11.598

4.  TRAF2 and TRAF3 independently mediate Ig class switching driven by CD40.

Authors:  Haifa H Jabara; Yu Weng; Tatyana Sannikova; Raif S Geha
Journal:  Int Immunol       Date:  2009-02-19       Impact factor: 4.823

Review 5.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 6.  TRAF6 activation in multiple myeloma: a potential therapeutic target.

Authors:  Hong Liu; Samantha Tamashiro; Stavroula Baritaki; Manuel Penichet; Youhua Yu; Haiming Chen; James Berenson; Benjamin Bonavida
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-03-21

7.  Increased IkappaB alpha expression is essential for the tolerogenic property of TGF-beta-exposed APCs.

Authors:  Paiman Ghafoori; Takeru Yoshimura; Bruce Turpie; Sharmila Masli
Journal:  FASEB J       Date:  2009-02-23       Impact factor: 5.191

8.  Spatiotemporal pattern of TRAF3 expression after rat spinal cord injury.

Authors:  Ya Wu; Minqian Zheng; Siqing Wang; Changzhi Song; Chuanbin Wang; Yueping Xiao; Lei Xu; Xiaozu Xu
Journal:  J Mol Histol       Date:  2014-05-07       Impact factor: 2.611

9.  Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.

Authors:  Christopher R Lucas; Hector M Cordero-Nieves; Robert S Erbe; Jaclyn W McAlees; Sumeena Bhatia; Richard J Hodes; Kerry S Campbell; Virginia M Sanders
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

10.  Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.

Authors:  Esther Lutgens; Dirk Lievens; Linda Beckers; Erwin Wijnands; Oliver Soehnlein; Alma Zernecke; Tom Seijkens; David Engel; Jack Cleutjens; Anna M Keller; Shalin H Naik; Louis Boon; Hafid Ait Oufella; Ziad Mallat; Cory L Ahonen; Randolph J Noelle; Menno P de Winther; Mat J Daemen; Erik A Biessen; Christian Weber
Journal:  J Exp Med       Date:  2010-01-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.